Prenetics Global (Prenetics Global) Combined Ratio % : 92.80% (As of Jun. 2019)

View and export this data going back to 2022. Start your Free Trial

What is Prenetics Global Combined Ratio %?

Combined Ratio % is a profitability metric of an insurance company to measure its performance in daily operations. It measures the money flowing out of an insurance company in the form of dividends, expenses, and losses.

Prenetics Global's Combined Ratio % for the quarter that ended in Jun. 2019 was 92.80% , which is lower than 93.80% for the pervious quarter ended in Jun. 2018.

The historical rank and industry rank for Prenetics Global's Combined Ratio % or its related term are showing as below:

PRE's Combined Ratio % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Combined Ratio % only.

Prenetics Global Combined Ratio % Historical Data

The historical data trend for Prenetics Global's Combined Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prenetics Global Combined Ratio % Chart

Prenetics GlobalQuarterly Data

Trend

Jun17

Sep17

Mar18

Jun18

Jun19

Combined Ratio %

Get a 7-Day Free Trial

Expense Ratio %

Get a 7-Day Free Trial

Claims Ratio %

Get a 7-Day Free Trial

Competitive Comparison of Prenetics Global's Combined Ratio %

For the Diagnostics & Research subindustry, Prenetics Global's Combined Ratio %, along with its competitors' market caps and Combined Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prenetics Global (NAS:PRE) Combined Ratio % Calculation

Combined Ratio % is calculated as:

Combined Ratio %

( Incurred Losses

Expenses )

Earned Premium

100%

Prenetics Global (NAS:PRE) Combined Ratio % Explanation

Combined Ratio % measures the money flowing out of an insurance company in the form of dividends, expenses and losses. A ratio below 100 percent suggests that the company is making an underwriting profit, while a ratio above 100 percent means that it paid more in the claim than it received. However, a ratio above 100 percent does not necessarily mean the company is losing money because the investment income is not included in the calculation.

Compared to Claims Ratio % and Expense Ratio %, the combined ratio is most important because it provides a comprehensive measure of an insurer's profitability.

Prenetics Global Combined Ratio % Related Terms

Thank you for viewing the detailed overview of Prenetics Global's Combined Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Prenetics Global (Prenetics Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prenetics Global Ltd (NAS:PRE) » Definitions » Combined Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong, HKG

Website

https://www.prenetics.com

Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.